Apricus Biosciences, Inc. (the “Company”) values individual privacy and we want to give our website visitors the opportunity to know what information we collect about them and how they can limit the use of personally identifiable information beyond the purposes for which they first provided it.
At all times, however, the Company reserves the right to disclose information when required by law or to comply with a valid legal process (such as a search warrant, subpoena or court order), to protect the Company’s rights or property, including without limitation in the event of a transfer of control of the Company or substantially all of its assets, or during emergencies when safety is at risk.
- Data We Collect and How We Use It.
- Children’s Privacy. The Company’s website is intended for adults. The Company does not knowingly collect personal information from children under the age of 13.
- Cookies & Computer-Related Information. The Company does not enable “cookies” on our website with one exception. A cookie is used in website system administration to keep track of movement of an individual user from one screen to another. This information may be used by our staff to detect and resolve website problems and to assist with customer support. We do not collect any personally identifiable information about site visitors in this process. Our web server automatically collects information from your computer and navigation patterns when you visit our site, including your Internet Protocol (IP) address, the computer’s operating system, the type of browser you use and the specific web pages visited during your connection. We may also track data such as the total number of visits to our website and the number of visitors to each page of our website. We may use this information, in aggregate form, for system maintenance and to better understand how our visitors use our site and services so that we can make them better. The Company may also share statistical or demographic information in aggregate form with third parties for marketing or research purposes. This aggregate data will not contain any information that personally identifies you.
- How You Can Control & Update Data About You. You may choose at any time to remove your name, telephone and fax numbers, and postal and email addresses from the lists we use to send notices or updates and elect not to receive correspondence from us by using the unsubscribe function found on the website. Other Internet sites you visit, including those linked from the Company website, may have their own privacy policies or no policy at all. Other websites might use personal information differently than our policy permits. We strongly encourage you to review the privacy policies of any site before providing any personal information.
FORWARD LOOKING STATEMENT
This website and the conference calls, press releases, presentations and other materials posted on, or available through, this website, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements that are not purely historical are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Apricus that any of its plans will be achieved. Such forward-looking statements include, among other things: the timing of the re-submission of the Vitaros NDA, including the need to address the issues raised by the FDA’s feedback or any issues raised by the Office of Product Quality related to the FDA’s determination that Vitaros is now a drug-device combination; Apricus’ plans for life-cycle development programs for Vitaros; Apricus’ development and partnering plans for RayVa™; Apricus’ plans to reduce operating expenses, including projected 2017 cost savings; Apricus’ strategic objectives, including efforts to regain compliance with NASDAQ listing standards; statements regarding the cash proceeds from the sale of its ex-U.S. Vitaros assets and rights to Ferring Pharmaceuticals and under the related transition services agreement; and the extinguishment of outstanding debt. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the FDA, including the Office of Product Quality, requiring additional clinical and pre-clinical data prior to the Vitaros NDA re-submission; Apricus’ ability to address any conditions for approvability raised by the FDA’s Office of Product Quality; the risk that the cost and other negative effects related to the reduction of Apricus’ workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from its current strategic focus, workforce reduction and other cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus’ ability to further develop Vitaros, such as delivery device improvements; Apricus’ ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; Apricus’ ability to achieve U.S. and Europe Orphan Designation for RayVa; the failure to meet NASDAQ continued listing requirements which could result in Apricus’ common stock being delisted from the exchange; Apricus’ ability to retain and attract key personnel; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to secure an ex-U.S. strategic partner for RayVa; disruption of Apricus’ business and diversion of its management’s time and attention in order to provide transition services under the transition services agreement with Ferring Pharmaceuticals; Apricus not realizing the full economic benefit from the ex-U.S. Vitaros asset sale transaction, including as a result of indemnification claims under the asset purchase agreement and the retention by Apricus’ of certain liabilities associated with the product business; long-term financial risks associated with selling Apricus’ commercialized and registered products; risks related to Apricus’ planned resubmission of the Vitaros NDA; other risks detailed in Apricus’ public periodic filings with the SEC; and market conditions. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as prediction of future events. All forward-looking statements are qualified in their entirety by this cautionary statement, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable conference calls, press releases, presentations and other materials. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available free of charge in the “Why Invest – SEC Filings” portion of this website or from the SEC’s website at www.sec.gov.